MB Therapeutics announces today that it has obtained the French Tech Emergence Grant (BFTE) to fund the development of an automated production solution for personalized medicines using pharmaceutical 3D printing.

With the support of the BPI, MB Therapeutics is fully committed to advancing its innovative solution. This solution will allow patients to benefit from next-generation medicines produced by 3D printing technology. This step reinforces MB Therapeutics' position as a pioneer in the sector, determined to revolutionize the way medicines are manufactured.